

Jean-Pierre CHANGEUX et al.
Serial No. 09/349,925

Attorney Docket No. 3495.0135-02

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-52 (Canceled).

53. (Currently Amended) The process according to claim 48, A process for producing a neuronal host cell that expresses a heterologous polypeptide, comprising transferring to the neuronal host cell a DNA sequence comprising a promoter of a $\beta 2$ -subunit of neuronal nicotinic acetylcholine receptor having the sequence from about nucleotide -1125 to about nucleotide +38 of SEQ ID NO. 22 operatively linked to a nucleotide sequence encoding the heterologous polypeptide under suitable conditions to cause expression of the heterologous polypeptide by the neuronal host cell, wherein the heterologous polypeptide is an oncogenic protein or is encoded by a reporter gene, and wherein the DNA sequence is transferred to the neuronal host cell in vitro.

54. (Previously Presented) The process according to claim 53, wherein the heterologous polypeptide is an oncogenic protein.

Claims 55-62 (Canceled).

63. (New) The process according to claim 53, wherein the heterologous polypeptide is encoded by a reporter gene.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNN LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com